Shin Poong Pharm.Co.Ltd. (019170) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shin Poong Pharm.Co.Ltd. (019170) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩8.94 Billion ≈ $6.06 Million USD) by net assets (₩264.20 Billion ≈ $179.05 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shin Poong Pharm.Co.Ltd. - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Shin Poong Pharm.Co.Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 019170 total liabilities for a breakdown of total debt and financial obligations.
Shin Poong Pharm.Co.Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shin Poong Pharm.Co.Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ASTON MART.LA.UADR LS-001
F:A5S0
|
-0.152x |
|
BP p.l.c
LSE:BP-B
|
0.103x |
|
PHOENIX N AG
SW:PMN
|
0.046x |
|
Shinhsiung Natural Gas
TWO:8908
|
-0.015x |
|
Mercurity Fintech Holding Inc ADR
NASDAQ:MFH
|
-0.118x |
|
Beijing Jiaoda Signal Technology
SHE:300851
|
0.015x |
|
Altek Corp
TW:3059
|
-0.007x |
|
Shenyang Huitian Thermal Power Co Ltd
SHE:000692
|
-1.010x |
Annual Cash Flow Conversion Efficiency for Shin Poong Pharm.Co.Ltd. (2004–2024)
The table below shows the annual cash flow conversion efficiency of Shin Poong Pharm.Co.Ltd. from 2004 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Shin Poong Pharm.Co.Ltd. worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩258.09 Billion ≈ $174.90 Million |
₩-15.15 Billion ≈ $-10.27 Million |
-0.059x | +35.91% |
| 2023-12-31 | ₩270.78 Billion ≈ $183.51 Million |
₩-24.81 Billion ≈ $-16.81 Million |
-0.092x | -14.59% |
| 2022-12-31 | ₩330.76 Billion ≈ $224.15 Million |
₩-26.44 Billion ≈ $-17.92 Million |
-0.080x | +60.09% |
| 2021-12-31 | ₩354.56 Billion ≈ $240.28 Million |
₩-71.03 Billion ≈ $-48.13 Million |
-0.200x | -473.78% |
| 2020-12-31 | ₩374.33 Billion ≈ $253.68 Million |
₩20.06 Billion ≈ $13.60 Million |
0.054x | -42.08% |
| 2019-12-31 | ₩209.13 Billion ≈ $141.72 Million |
₩19.35 Billion ≈ $13.11 Million |
0.093x | -40.11% |
| 2018-12-31 | ₩207.48 Billion ≈ $140.61 Million |
₩32.05 Billion ≈ $21.72 Million |
0.154x | +219.87% |
| 2017-12-31 | ₩210.11 Billion ≈ $142.39 Million |
₩10.15 Billion ≈ $6.88 Million |
0.048x | -44.76% |
| 2016-12-31 | ₩216.85 Billion ≈ $146.96 Million |
₩18.96 Billion ≈ $12.85 Million |
0.087x | +72.25% |
| 2015-12-31 | ₩194.86 Billion ≈ $132.05 Million |
₩9.89 Billion ≈ $6.70 Million |
0.051x | +20285.40% |
| 2014-12-31 | ₩191.51 Billion ≈ $129.79 Million |
₩-48.16 Million ≈ $-32.64K |
0.000x | -100.42% |
| 2013-12-31 | ₩190.79 Billion ≈ $129.29 Million |
₩11.45 Billion ≈ $7.76 Million |
0.060x | -63.21% |
| 2012-12-31 | ₩188.73 Billion ≈ $127.90 Million |
₩30.79 Billion ≈ $20.87 Million |
0.163x | +2.16% |
| 2011-12-31 | ₩179.86 Billion ≈ $121.89 Million |
₩28.73 Billion ≈ $19.47 Million |
0.160x | +111.50% |
| 2010-12-31 | ₩150.39 Billion ≈ $101.92 Million |
₩11.36 Billion ≈ $7.70 Million |
0.076x | +11.76% |
| 2009-12-31 | ₩145.31 Billion ≈ $98.48 Million |
₩9.82 Billion ≈ $6.65 Million |
0.068x | -63.33% |
| 2008-12-31 | ₩127.93 Billion ≈ $86.70 Million |
₩23.57 Billion ≈ $15.97 Million |
0.184x | +114.71% |
| 2007-12-31 | ₩113.81 Billion ≈ $77.12 Million |
₩9.77 Billion ≈ $6.62 Million |
0.086x | -14.81% |
| 2006-12-31 | ₩106.28 Billion ≈ $72.02 Million |
₩10.71 Billion ≈ $7.25 Million |
0.101x | +99.59% |
| 2005-12-31 | ₩97.65 Billion ≈ $66.18 Million |
₩4.93 Billion ≈ $3.34 Million |
0.050x | -57.97% |
| 2004-12-31 | ₩87.36 Billion ≈ $59.20 Million |
₩10.49 Billion ≈ $7.11 Million |
0.120x | -- |
About Shin Poong Pharm.Co.Ltd.
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more